Gamida Cell Announces Positive Topline Data on Secondary Endpoints from Phase 3 Clinical Study of Omidubicel in Patients with Hematologic Malignancies – Watertown Public Opinion

BOSTON–(BUSINESS WIRE)–Oct 6, 2020–

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that the Phase 3 study of omidubicel,
Source…